Assistance Publique – Hôpitaux de Paris is the leading university hospital center in Europe. With three missions, to care, to train, to research and to innovate, the AP-HP takes care of all the people who come to its hospitals, trains the professionals of today and tomorrow and is a major player in research.
About the solution
The AP-HP, through its status as a university hospital, has the mission to innovate. The search for new solutions to contribute to the well-being of patients, their loved ones and the professionals who support them is one of its primary missions. It supports and accompanies several forms of health innovation whoever it is.
Oxeltis is a medicinal chemistry services company created in 2010 in Montpellier, France, by former researchers from Idenix Pharmaceuticals (formerly MSD). The company has a small-scale custom synthesis business and hit and lead optimization services in various areas, such as antivirals, antibiotics, and anticancer compounds. Oxeltis’ scientific team comprises 21 experienced chemists with recognized expertise in specific areas of organic synthesis: heterocycles, macrocycles, nucleosides/nucleotides, phosphoramidites, iminosugars, modified sugars, oligosaccharides, and PROTACs. Oxeltis services includes also route scouting and up to 50-100g synthesis. Oxeltis works with European, Japanese, and North American start-ups, pharma companies, and research institutions.
About the solution
Oxeltis team is focused on speed of delivery, quality, and confidentiality of the services and collaborations it develops. Oxeltis has completed more than 35 projects with complex and multi-step synthetic chemistry for pharmaceutical and biotechnology companies, including five of the ten largest global pharmaceutical companies. Several drug candidates delivered to its customers are in clinical development.
InFlectis is a French-based drug discovery company, incoporated in 2013, developing first-in-class therapies for neurological rare diseases. They are in clinical development with an orally available small molecule that has the potential to extend lives or improve the quality-of-life for people suffering from ALS. They are also ready to enter in phase 2 clinical trial in Charcot-Marie-Tooth disease and preclinical proof of efficacy has been obtained in rare cerebellar ataxias.
About the solution
IFB-088 is a first-in-class orally available small molecule drug candidate with a validated mechanism of action and a promising pharmacokinetic profile capable of crossing the blood brain barrier to target the central and peripheral nervous system. IFB-088 is a multifunctional drug that modulates the PPP1R15A/PP1c phosphatase complex and inhibits NR2B-containing NMDAR. The potential of IFB-088 lies in its ability to target different major cellular pathophysiological mechanisms to manage disease progression: protein aggregation, oxidative stress, and glutamate excitotoxicity.
BrainTale is an innovative medtech company deciphering white matter to enable faster drug development and better brain care with clinically validated prognostic solutions. With non-invasive, sensitive and reliable measurements of white matter microstructure alterations, BrainTale offers a digital biomarkers platform to support clinical development programs and decision-making in clinical routine.
BrainTale enables the identification of patients at risk, early diagnosis and monitoring of disease progression and the effectiveness of treatments in neurology, in particular for demyelinating diseases such as Multiple Sclerosis and neurodegenerative diseases such as Alzheimer’s Diseases. Based on more than 15 years of research and development, BrainTale’s products are developed to meet the medical needs and expectations of pharma companies and healthcare professionals for the benefit of patients.
About the solution
BrainTale’s solutions enable access to diffusion MRI markers for drug development and patient care, through a unique technology that enables calibration and standardization of MRI diffusion parameters in a multidevice and multicenter setting. Thus, BrainTale offers quantification of white matter tissue, especially fiber density, axonal degeneration and myelin content, with unlimited potential to support clinical development programs through accurate patient selection and stratification at inclusion, and evaluation of treatment efficacy with highly sensitive and robust biomarkers.
ETAP-Lab is a preclinical CRO renowned for its expertise in the fields of dermatology, neurology, cardiology and gastroenterology. It assesses the effectiveness of drug candidates and medical devices.
Founded in 1991, ETAP-Lab has now worked with 150 companies ranging from small biotechs to large pharmaceutical groups, both in France and further afield. Ever since the company’s earliest days, ETAP-Lab models have consistently offered high translational value associated with relevant protocols. Mainly comprised of scientific experts, our team analyses client requirements, offering guidance and advice in the development of a tailor-made solution.
ETAP-Lab studies are conducted to exacting quality standards, ensuring the reproducibility, transparency and traceability of tests while maintaining responsiveness and offering regular dialogue with our project managers.
About the solution
ETAP-Lab can fast-track your pipeline with preclinical excellence having high predictability level through in vitro and in vivo testing and rodent behavioural analysis:
– DERMATOLOGY: Wide portfolio of original inflammatory (psoriasis, atopic dermatitis) and wound-healing in vivo models.
– CARDIOLOGY: In-depth in vivo studies of major cardiovascular diseases like Pulmonary Arterial Hypertension, Ischemia Reperfusion, and Heart failures.
– NEUROLOGY: Original and translational in vivo and in vitro models of Stroke and neurodegenerative diseases like Alzheimer’s and Parkinson’s models.
– GASTROENTEROLOGY: In vivo models of gastrointestinal disorders like irritable bowel syndrome (IBS) and traveler’s diarrhea. Expertise in metabolic disturbances such as diabetes, obesity, and malnutrition.
ClinSearch is a full service European CRO, established in 1999, offering clinical research and medical evaluation services throughout Europe, as well as the Middle East and the United States.
They have conducted hundreds of studies, from phase I to IV studies, early access programs, post-marketing studies, RWE, PASS, PAES, database analyses and medico-economic studies, involving 1 patient up to 220,000 subjects. Their customers include global and local medical device, biotechnology and pharmaceutical companies, as well as public health institutions.
About the solution
Full service offering from A to Z: methodological input to study design through to peer-reviewed publications, passing via in-house development of sophisticated healthcare tools (EDC, ePRO, …).
The in-house team of over 70 people work from our headquarters in Malakoff (France), but hail from ~15 different countries and speak over 10 languages, and are trained to a high standard (MD, PhD, PharmD, MS, MPH …).
Firalis Molecular Precision (FMP), established in 2019 and rooted in the Firalis Group, operates as a leading Contract Research Organization (CRO) from Huningue, France.
Specialized in biomarker discovery and multi-omic analysis (genomics, proteomics, metabolomics), FMP accelerates precision medicine by improving diagnostics, understanding disease mechanisms, and evaluating drug efficacy. With advanced laboratories and a dedicated team of over 55 experts, FMP supports biotech and pharma companies globally, offering a suite of services that span pre-clinical to clinical trials, thus playing a pivotal role in advancing healthcare innovations.
About the solution
Firalis Molecular Precision (FMP) is at the forefront of the multi-omics revolution bringing progress and innovation to the biopharmaceutical industry. By harnessing advanced -omics technologies and bioinformatics, they excel in identifying promising therapeutic targets and enhancing the drug development process for greater speed and reliability. Their state-of-the-art multi-omics solutions facilitate precise, high-throughput genomics, transcriptomics, and proteomics, leading to pioneering healthcare breakthroughs.
Lys Therapeutics is a pioneering biotechnology company dedicated to addressing unmet medical needs in patients afflicted with neurovascular or neurodegenerative disorders through a revolutionary approach targeting blood-brain barrier (BBB) dysfunction.
Lys Therapeutics’ approach of targeting neuroinflammation to combat neurodegeneration represents a promising avenue in the quest for effective treatments for these debilitating disorders.
About the solution
In the pathophysiology of various neurological diseases such as stroke, multiple sclerosis, and Parkinson’s disease, hyperactivation of endothelial NMDA receptors (NMDAr) by overexpressed tissue plasminogen activator (tPA) leads to the degradation of tight junctions and subsequent BBB dysfunction. This process allows inflammatory cells and toxic molecules to migrate into the brain parenchyma, triggering severe neuroinflammation and excitotoxicity, which are primary contributors to neurodegeneration.
Lys Therapeutics’ lead compound, LYS241, is a first-in-class monoclonal antibody with a groundbreaking mechanism of action that effectively counters these pathological mechanisms. Specifically, LYS241 acts within blood vessels to prevent the binding of tPA to NMDAr, without interfering with the physiological function of NMDA receptors. By inhibiting this interaction, NMDA receptors can function normally, thereby halting downstream deleterious cellular pathways. As a result, tight junctions are reinstated, endothelial cells regain their healthy state, and BBB function is restored, shielding the brain from further neuroinflammatory and subsequent neurodegenerative cascades.
HORIANA is a premier consulting companydedicated to epidemiology and biostatistics, specializing in designing and conducting Healthcare Real-World Studies.
Established by a team of seasoned experts, each with over 15 years of experience in Life Sciences, Horiana is at the forefront of providing comprehensive support to its clients. With a dedicated team of more than 25 experts, Horiana is well-positioned to assist clients at every phase of their projects. Their clients span both private and public/academic healthcare professionals.
At HORIANA, they are committed to excellence and quality, ensuring the success of their clients’ projects.
About the solution
Their main solutions are:
– Expertise and Consulting: Specialized guidance in epidemiology, pharmacoepidemiology, and biostatistics/data science. – Clinical and Observational Studies (on primary and secondary) – Enriched Studies: Integration of data from diverse sources through multisource studies and linked studies. – Evidence Synthesis: Conducting External Comparators such as Network Meta-Analysis (NMA) and Matching-Adjusted Indirect Comparison (MAIC). – Synthetic Control Groups: Implementation of Synthetic Control Groups and External Control Arms. – Training Programs: Certified QUALIOPI training center in Statistics & Epidemiology – IDMC, DSMB and Strategic consulting
Based on their unique vector platform, EG427 delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Their vectors can achieve focal and efficient transduction in specific regions and then selective expression of transgenes in targeted subsets of neurons thanks to the control of sophisticated regulatory elements. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of nrHSV-1 vectors allows for either long-term gene therapy or all-in-one gene editing approaches.
About the solution
EG427 is the second company to reach the clinical development stage with a non-replicating HSV-1 vector. They are filing a US IND and a UK CTA in early 2Q-2024 and initiating a phase 1B/2A trial to demonstrate safety and efficacy. This first product, EG110A, addresses multiple severe bladder diseases (including Neurogenic Detrusor Overactivity and Refractory Overactive Bladder) by selectively inhibiting targeted sensory neurons. It has the potential to be a major improvement over existing therapies, resulting in better care for the patients and lower costs for healthcare systems. EG110A serves a very large, unsatisfied market that nevertheless represents over $3.7B in revenues for existing therapeutic modalities.
